AMRX

Amneal Pharmaceuticals, Inc. Class A Common Stock

19.33

USD

-0.17

-0.87%

Sep 23, 15:59 UTC -4

Closed

After-Market

19.77

+0.44

+2.28%

AMRX Earnings Reports

Positive Surprise Ratio

AMRX beat 29 of 43 last estimates.

67%

Next Report

Date of Next Report

Oct 28, 2026

Estimate for Q3 26 (Revenue/ EPS)

$829.12M

$0.23

Implied change from Q2 26 (Revenue/ EPS)

+4.13%

-23.33%

Implied change from Q3 25 (Revenue/ EPS)

+5.69%

+35.29%

Amneal Pharmaceuticals, Inc. Class A Common Stock earnings per share and revenue

On Jul 30, 2026, AMRX reported earnings of 0.30 USD per share (EPS) for Q2 26, beating the estimate of 0.22 USD, resulting in a 32.80% surprise. Revenue reached 796.20 million, compared to an expected 783.57 million, with a 1.61% difference. The market reacted with a -3.14% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 6 analysts forecast an EPS of 0.23 USD, with revenue projected to reach 829.12 million USD, implying an decrease of -23.33% EPS, and increase of 4.13% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Champions Oncology, Inc.

Report Date

Sep 10, 2026 For Q1 27

Estimate

-$0.01

Actual

-$0.03

Surprise

-194.12%

PharmaCyte Biotech, Inc. Common Stock

Report Date

Sep 14, 2026 For Q1 27

Estimate

Actual

-$0.54

Surprise

FAQ

What were Amneal Pharmaceuticals, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Amneal Pharmaceuticals, Inc. Class A Common Stock reported EPS of $0.30, beating estimates by 32.8%, and revenue of $796.20M, 1.61% above expectations.

How did the market react to Amneal Pharmaceuticals, Inc. Class A Common Stock's Q2 2026 earnings?

The stock price moved down -3.14%, changed from $19.10 before the earnings release to $18.50 the day after.

When is Amneal Pharmaceuticals, Inc. Class A Common Stock expected to report next?

The next earning report is scheduled for Oct 28, 2026.

What are the forecasts for Amneal Pharmaceuticals, Inc. Class A Common Stock's next earnings report?

Based on 6 analysts, Amneal Pharmaceuticals, Inc. Class A Common Stock is expected to report EPS of $0.23 and revenue of $829.12M for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.